Protocol No.UW25107
BCA101X301
Principal InvestigatorBruce, Justine
PhaseII/III
Age GroupAdult
ClinicalTrials.GovNCT06788990 (Click to jump to clinicaltrials.gov)
Management Group(s) Thoracic

Title
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Description

Objective

Treatment

Key Eligibility

Applicable Disease Sites
Head and Neck

Participating Institutions
UW Health Eastpark Medical Center; UW Health University Hospital